ENSC (Ensysce Biosciences) Other Operating Expense: $-4.71 Mil (TTM As of Mar. 2026)


ENSC Ensysce Biosciences Inc ENSC
23 GF Score
Price $0.28
! 2 Warning Signs
View Full Analysis

What is Ensysce Biosciences Other Operating Expense?

Ensysce Biosciences ENSC +0.73% 23 Other Operating Expense is $-4.71 Mil as of Mar. 2026. GuruFocus rates ENSC with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

Ensysce Biosciences's Other Operating Expense for the three months ended in Mar. 2026 was $-0.96 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-4.71 Mil.

Ensysce Biosciences's quarterly Other Operating Expense declined from Sep. 2025 ($-0.49 Mil) to Dec. 2025 ($-1.88 Mil) but then increased from Dec. 2025 ($-1.88 Mil) to Mar. 2026 ($-0.96 Mil).

Ensysce Biosciences's annual Other Operating Expense declined from Dec. 2023 ($-2.23 Mil) to Dec. 2024 ($-5.21 Mil) but then increased from Dec. 2024 ($-5.21 Mil) to Dec. 2025 ($-5.07 Mil).

Ensysce Biosciences Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Ensysce Biosciences's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ensysce Biosciences Other Operating Expense Chart

Ensysce Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial -3.53 -2.52 -2.23 -5.21 -5.07

Ensysce Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.32 -1.37 -0.49 -1.88 -0.96
ENSC
23GF Score
Ensysce Biosciences Inc ENSC
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ensysce Biosciences Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $-4.71 Mil mean?
Ensysce Biosciences (ENSC) has a Other Operating Expense of $-4.71 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Ensysce Biosciences and its competitors.
Is Ensysce Biosciences' Other Operating Expense too high?
Ensysce Biosciences' current Other Operating Expense is $-4.71 Mil. Overall, Ensysce Biosciences has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Ensysce Biosciences' Other Operating Expense compare to RNAZ and ALZN?
Ensysce Biosciences' Other Operating Expense of $-4.71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Ensysce Biosciences and its competitors. Ensysce Biosciences's current Other Operating Expense is $-4.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ensysce Biosciences stock overvalued right now?
Ensysce Biosciences (ENSC) has a current Other Operating Expense of $-4.71 Mil. The current Other Operating Expense is $-4.71 Mil. Ensysce Biosciences' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Ensysce Biosciences (ENSC), the current Other Operating Expense is $-4.71 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ensysce Biosciences Business Description

Address 7946 Ivanhoe Avenue, Suite 201, La Jolla, CA, USA, 92037
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
23GF Score

Get the complete analysis for ENSC

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28
Price